Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural ...

For the past 50 years, the threshold for diagnosing HCM has been 15mm for everyone. If the muscle is thicker than this, the ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Echocardiograms, which are about 90% effective at finding HCM, are the first-line standard when it comes to diagnosing the ...

Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize ...

for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment ...

This webinar will focus on what is on the horizon for the treatment and care of HCM as part of the Hypertrophic Cardiomyopathy: Accelerating Guideline-Driven Care grant and will be moderated by ...